Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

HIV Infection

Free Subscription Articles published in Clin Infect Dis Retrieve available abstracts of 256 articles: HTML format

Single Articles

September 2025
1. MARTINEZ MARTIN P, Esteban-Cantos A, Jurado F, Montejano R, et al
   Prognostic value of blood epigenetic biomarkers of aging in persons with well controlled HIV infection.
   Clin Infect Dis. 2025 Sep 30:ciaf537. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. DURSTENFELD MS
   REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks.
   Clin Infect Dis. 2025 Sep 26:ciaf543. doi: 10.1093.
   PubMed    
   
   
   
3. GRINSPOON SK, Zhao S, Martinez E, Fichtenbaum CJ, et al
   Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2.
   Clin Infect Dis. 2025 Sep 26:ciaf542. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. BOLDUC P, Barakat LA, Sherman EM, Day PG, et al
   Promoting Human Immunodeficiency Virus Syndemic Care in Health Professions Education: Linking Workforce Demands to the Aspirations of a Rising Generation.
   Clin Infect Dis. 2025 Sep 23:ciaf347. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. LLIBRE JM, Ripamonti D, Geretti AM, Martin-Iguacel R, et al
   Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens.
   Clin Infect Dis. 2025 Sep 23:ciaf471. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. LEOCADIO C, Garcia E, Lash M, Berardi J, et al
   Clinical Outcomes of Mpox Disease in Patients Treated with Tecovirimat.
   Clin Infect Dis. 2025 Sep 19:ciaf520. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. MANN SC, Lykins D, Coyle RP, Witt MD, et al
   In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort.
   Clin Infect Dis. 2025 Sep 17:ciaf509. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. MAINARDI I, Gerevini S, Tarantino A, Vercesi R, et al
   Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study.
   Clin Infect Dis. 2025 Sep 9:ciaf501. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. BECK IA, Boyce CL, Bishop MD, Oldroyd AR, et al
   HIV resistance to dolutegravir varies with co-administered agents.
   Clin Infect Dis. 2025 Sep 2:ciaf481. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. BARDA B, Bongiovanni M
    Long-acting cabotegravir/rilpivirine in viraemic people with HIV: bumpy raod to perfection.
    Clin Infect Dis. 2025 Sep 1:ciaf482. doi: 10.1093.
    PubMed    
    
    
    
11. DAVIES SMITH E, Douglas PS, McCallum S, Troendle J, et al
    Win ratio aligns with and enhances interpretation of REPRIEVE's primary findings.
    Clin Infect Dis. 2025 Sep 1:ciaf477. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. SEIBERT AM, Matheu M, Buckel WR, Bledsoe J, et al
    Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative.
    Clin Infect Dis. 2025 Sep 1:ciaf434. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
13. MAKUZA JD, Jeong D, Law M, Puyat JH, et al
    HBV Care Cascade in Rwanda: A Population-based Study From 2016-2023.
    Clin Infect Dis. 2025 Aug 29:ciaf393. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. FIGUEROA MI, Brites C, Cecchini D, Ramalho A, et al
    Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
    Clin Infect Dis. 2025 Aug 28:ciaf415. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. WATERS LJ
    DOLCE: Sweet Success for Dolutegravir/Lamivudine?
    Clin Infect Dis. 2025 Aug 28:ciaf416. doi: 10.1093.
    PubMed    
    
    
    
16. POORE H, Wambi P, Nkereuwem E, Nakafeero J, et al
    The three-gene Xpert Host Response signature for pediatric tuberculosis screening: A prospective diagnostic accuracy study.
    Clin Infect Dis. 2025 Aug 21:ciaf445. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. ZHANG L, Wu X, He Y, Song Y, et al
    Impact of different INSTIs on BMI among people living with HIV who newly started ART in Shenzhen, China: a real-world data analysis.
    Clin Infect Dis. 2025 Aug 20:ciaf466. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. PARK SY, Takayama C, Ryu J, Sattah M, et al
    Design and evaluation of next-generation HIV genotyping for detection of resistance mutations to 28 antiretroviral drugs across five major classes including lenacapavir.
    Clin Infect Dis. 2025 Aug 19:ciaf458. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. COBURN SB, Silverberg MJ, Lang R, Lesko C, et al
    Clinical predictors and incidence of Kaposi sarcoma among males with HIV in the Treat-all era in the United States and Canada.
    Clin Infect Dis. 2025 Aug 18:ciaf446. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. NEANT N, Le MP, Bouchet S, Lagoutte-Renosi J, et al
    Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study.
    Clin Infect Dis. 2025 Aug 18:ciaf385. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. DAVIS JM, Green E, Solomon DA
    A Blurry Line: Navigating Treatment Decisions When the Guidelines Don't Fit.
    Clin Infect Dis. 2025 Aug 14:ciaf396. doi: 10.1093.
    PubMed    
    
    
    
22. PARIENTI JJ
    Background HIV Incidence in PURPOSE 1 and 2 PrEP trials.
    Clin Infect Dis. 2025 Aug 14:ciaf436. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. NUTT CT, Lessells RJ, Muyindike WR, Johnson LS, et al
    Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries with the Highest Adult HIV Prevalence.
    Clin Infect Dis. 2025 Aug 11:ciaf444. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. RUTAKINGIRWA MK, Skipper CP, Dai B, Wele A, et al
    Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial.
    Clin Infect Dis. 2025 Aug 7:ciaf432. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. RON R, Diaz-Garcia C, Sendagorta E, Cabello-Ubeda A, et al
    A Phase IV, open-label, single-arm, multicentric clinical trial for evaluation of Human Papillomavirus 9vHPV vaccine immunogenicity in Men Who Have Sex with Men living with HIV: GeSIDA Study 10017.
    Clin Infect Dis. 2025 Aug 6:ciaf435. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. SCHNYDER JL, Haggenburg S, Garcia Garrido HM, Reiners A, et al
    Long-term immunogenicity and boostability of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in adults receiving immunosuppressive therapy and adults living with HIV - 3-year follow-up of a pr
    Clin Infect Dis. 2025 Aug 6:ciaf438. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. PEI PP, Jones M, Hu R, Chen W, et al
    Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US.
    Clin Infect Dis. 2025 Aug 4:ciaf428. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. DRUMEL T, Sourice J, Allavena C, Rodallec A, et al
    Kinetics of non-nucleoside reverse transcriptase inhibitor resistance-associated mutations in HIV-1 proviral cellular reservoirs in NNRTI-experienced persons.
    Clin Infect Dis. 2025 Aug 4:ciaf430. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. GIACOMELLI A, Capra N, Lolatto R, Gagliardini R, et al
    All-Cause Mortality in People with Four-Class Drug-Resistant HIV: A Matched Cohort Analysis with Data from the PRESTIGIO Registry.
    Clin Infect Dis. 2025 Aug 1:ciaf421. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. COLASANTI JA, Aldredge A, Niles-Carnes LV, Ochieng E, et al
    Long-acting cabotegravir/rilpivirine, lenacapavir, and ibalizumab use among persons with HIV-1 viremia at a Ryan White-funded clinic in the urban U.S. South.
    Clin Infect Dis. 2025 Aug 1:ciaf425. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
31. WIRDEN M, Guihot A, Gautheret-Dejean A, Sterlin D, et al
    Consequences of stopping antiretroviral treatment in a persistently seronegative individual infected with HIV-1.
    Clin Infect Dis. 2025 Jul 31:ciaf422. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. KIM AY, Kang M, Umbleja T, Nunes EP, et al
    Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.
    Clin Infect Dis. 2025 Jul 30:ciaf305. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. BERENGUER J, Fanciulli C, Arcos MM, Vivancos MJ, et al
    Trends in HCV Infection Prevalence Among People with HIV in Spain Over Two Decades (2002-2023).
    Clin Infect Dis. 2025 Jul 24:ciaf407. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. BEZUIDENHOUT C, Long L, Nichols B, Meyer-Rath G, et al
    Sputum and tongue swab molecular testing for the in-home diagnosis of tuberculosis in unselected household contacts: a cost and cost-effectiveness analysis.
    Clin Infect Dis. 2025 Jul 24:ciaf389. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. CHISSUMBA RM, Kwatra G, Ramgi P, Enosse M, et al
    Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.
    Clin Infect Dis. 2025;80.
    PubMed     Abstract available
    
    
    
36. DE SCHACHT C, Capitine IU, Lucas C, Muteerwa A, et al
    Importance of Targeted Communication Strategies During COVID-19 Vaccination Campaigns in Mozambique: Results of a Mixed-Methods Acceptability Study.
    Clin Infect Dis. 2025;80.
    PubMed     Abstract available
    
    
    
37. ROCKMAN L, Abdulgader SM, Minnies S, Palmer Z, et al
    Oral washes and tongue swabs for Xpert MTB/RIF Ultra-based tuberculosis diagnosis in people with and without the ability to make sputum.
    Clin Infect Dis. 2025 Jul 18:ciaf397. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. ANDREWS HS, Murthy M, Davis BT
    State-of-the-Art Review: Anal Cancer Screening in People With HIV.
    Clin Infect Dis. 2025;80:e80-e88.
    PubMed     Abstract available
    
    
    
39. ANDREWS HS, Murthy M, Davis BT
    Executive Summary: State-of-the-Art Review: Anal Cancer Screening in People With HIV.
    Clin Infect Dis. 2025;80:1177-1178.
    PubMed    
    
    
    
40. SCHOEPF IC, Baltisberger V, Thorball CW, Ryom L, et al
    Low Trauma Fractures in People with HIV: Longitudinal Time Trends in the Swiss HIV Cohort Study 2009-2022.
    Clin Infect Dis. 2025 Jul 17:ciaf392. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. TAIWO BO, Zheng Y, Rodriguez K, Burke L, et al
    Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults with HIV-1: ACTG A5357.
    Clin Infect Dis. 2025 Jul 15:ciaf375. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. ZHU L, Furukawa NW, Thompson WW, Reitsma MB, et al
    Potential impact of frequent testing for hepatitis C virus among people who inject drugs toward hepatitis C elimination in the United States.
    Clin Infect Dis. 2025 Jul 15:ciaf368. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. TAN B, Webster H, Krishnaswamy S, MacPhail A, et al
    Outcomes of critical illness in peoples with Advanced HIV Disease: 30 years of binational data.
    Clin Infect Dis. 2025 Jul 4:ciaf362. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. BROWN TT, Arao RF, Warsi M, Phanuphak N, et al
    Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083.
    Clin Infect Dis. 2025 Jul 1:ciaf221. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
45. NYEIN PP, Borok M, Eriobu N, Kaplan R, et al
    A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week resul
    Clin Infect Dis. 2025 Jun 27:ciaf346. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. COLLINS LF, Christopoulos KA, McNulty MC, Colasanti JA, et al
    Comparing interest in thigh administration of long-acting cabotegravir/rilpivirine among hypothetical users, early adopters and trial participants with experience.
    Clin Infect Dis. 2025 Jun 25:ciaf333. doi: 10.1093.
    PubMed    
    
    
    
47. TUGUME L, Cresswell FV, Engen NW, Tukundane A, et al
    Prognostic Value of C-Reactive Protein in Adults With Tuberculous Meningitis: A Prospective Cohort Study.
    Clin Infect Dis. 2025 Jun 24:ciaf261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. PATAMATAMKUL S
    Should ART Be Interrupted in Recently Initiated Persons With Recently Diagnosed HIV-Associated Cryptococcal Meningitis?
    Clin Infect Dis. 2025 Jun 24:ciaf226. doi: 10.1093.
    PubMed    
    
    
    
49. VAN ZYL GU, Decloedt E, Jennings L, Kellermann T, et al
    A real-time urine tenofovir assay improves drug adherence among people with HIV with prior virologic failure in a randomized controlled trial.
    Clin Infect Dis. 2025 Jun 20:ciaf337. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. CORLEY MJ, Watanabe M, Pang APS, Dwaraka VB, et al
    Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial.
    Clin Infect Dis. 2025 Jun 18:ciaf247. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. LU X, Jiang Y, Zhang R, Zhang Y, et al
    Epidemiologic and Bacterial Factors Facilitating Long-Term Transmission of Multidrug-Resistant Tuberculosis in Shanghai, China.
    Clin Infect Dis. 2025 Jun 18:ciaf313. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. AGARWAL R, Nyendak M, Chava N, Allam RR, et al
    Long-term protection from TB preventive treatment among people with HIV in a high-burden tuberculosis setting: an observational cohort study from India.
    Clin Infect Dis. 2025 Jun 16:ciaf322. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. SHAPIRO L, Henao-Martinez AF
    Letter to the Editor: Re-evaluating Immune-Based Strategies for Cryptococcal Meningitis in Non-HIV Populations.
    Clin Infect Dis. 2025 Jun 16:ciaf326. doi: 10.1093.
    PubMed    
    
    
    
54. HAW NJL, Lesko CR, Ng DK, Lam JO, et al
    Incidence of AIDS-defining Conditions among Adults with Perinatally Acquired HIV after Transition to Adult HIV Care in the United States and Canada, 2000-2022.
    Clin Infect Dis. 2025 Jun 5:ciaf300. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. JAGANATH D, Nabeta P, Nicol MP, Castro R, et al
    Stool processing methods for Xpert Ultra testing in childhood tuberculosis: A prospective, multi-country accuracy study.
    Clin Infect Dis. 2025 Jun 3:ciaf289. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. CROWELL TA, Hsieh HC, Agan BK
    New Data and Next Steps for Clarifying how the Timing of Antiretroviral Therapy Initiation Influences Viral Blips and HIV Reservoir Size.
    Clin Infect Dis. 2025 Jun 3:ciaf273. doi: 10.1093.
    PubMed    
    
    
    May 2025
57. AUDSLEY J, Avihingsanon A, Li X, Edwards R, et al
    Kinetics and predictors of Hepatitis B surface antigen (HBsAg) loss after commencing HBV-active antiretroviral therapy (ART) in the setting of HIV-and chronic HBV co-infection.
    Clin Infect Dis. 2025 May 31:ciaf281. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. PURCHASE SE, Brigden J, Seddon JA, Martinson NA, et al
    Risk of tuberculosis infection in young children exposed to multidrug-resistant tuberculosis in the TB-CHAMP multi-site randomised controlled trial.
    Clin Infect Dis. 2025 May 29:ciaf284. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. ANDREWS HS, Blanchard HL, Yang S, Utay NS, et al
    Low Rate of Documented Measles Immunity in a Large Urban HIV Clinic.
    Clin Infect Dis. 2025 May 28:ciaf278. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. HALL EW, Sandul AL, Kamili S, Cartwright EJ, et al
    Cost-Effectiveness Analysis of Testing Approaches for Diagnosis of Hepatitis C Among US Adults.
    Clin Infect Dis. 2025 May 21:ciaf166. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. LOOSLI T, Moore CB, Buzaalirwa L, Byakwaga H, et al
    Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.
    Clin Infect Dis. 2025 May 20:ciaf204. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. STURNY-LECLERE A, Francoise U, Badje AD, Garcia-Hermoso D, et al
    Histoplasma antigenuria prevalence in patients with advanced HIV disease in Cote d'Ivoire: a prospective trial ancillary study.
    Clin Infect Dis. 2025 May 16:ciaf237. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. ODEYEMI Y, Tekin A, Schanz C, Schreier D, et al
    Comparative effectiveness of azithromycin versus doxycycline in hospitalized patients with community acquired pneumonia treated with beta-lactams: A multicenter matched cohort study.
    Clin Infect Dis. 2025 May 16:ciaf252. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. HAN WM, Ryom L, Sabin CA, Greenberg L, et al
    Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohort.
    Clin Infect Dis. 2025 May 15:ciaf248. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. SCHWARTZ IS, Pasqualotto AC
    Histoplasma antigen screening in advanced HIV disease.
    Clin Infect Dis. 2025 May 13:ciaf238. doi: 10.1093.
    PubMed    
    
    
    
66. KONOPNICKI D, Gilles C, Manigart Y, Barlow P, et al
    Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial.
    Clin Infect Dis. 2025 May 13:ciaf241. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. HAWKINS KL, Dandachi D, Verzani Z, Brannock MD, et al
    HIV Infection and Long COVID: A RECOVER Program, Electronic Health Record Based Cohort Study.
    Clin Infect Dis. 2025 May 12:ciaf242. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. STADLER JAM, Kuhlin JJ, Molloy SF, Mtwa NN, et al
    Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.
    Clin Infect Dis. 2025 May 9:ciaf112. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. SPINELLI MA, Heise MJ, Roman J, Bena J, et al
    Sustained Effectiveness of Doxycycline Post-Exposure-Prophylaxis in a Large Sexual Health Clinic over 96 Weeks: An Interrupted Time Series Analysis.
    Clin Infect Dis. 2025 May 6:ciaf234. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. NAMBIAR P, Liang T, Labo N, Hand J, et al
    Kaposi Sarcoma-Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients with HIV in the United States.
    Clin Infect Dis. 2025 May 5:ciaf229. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. ZHU W, Delaney K, Huang YA, Patel RR, et al
    HIV RNA testing to monitor oral PrEP use does not add clinical value: a real-world cohort study-United States, 2019-2023.
    Clin Infect Dis. 2025 May 5:ciaf230. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
72. OMBAJO LA, Penner J, Nkuranga J, Omodi V, et al
    Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial.
    Clin Infect Dis. 2025;80:889-892.
    PubMed     Abstract available
    
    
    
73. HAO J, Liu X, Wang D, Hu H, et al
    Transmitted Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey.
    Clin Infect Dis. 2025 Apr 29:ciaf159. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. LARSSON L, Calderwood CJ, Marambire ET, Held K, et al
    Body mass index trajectories and association with tuberculosis risk in a cohort of household contacts in Southern Africa.
    Clin Infect Dis. 2025 Apr 28:ciaf222. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. GRINSPOON SK, Watanabe M, Ribaudo HJ, Bloomfield GS, et al
    Factors Affecting Risk of CVD Events in a Global CVD Prevention Cohort of People with HIV.
    Clin Infect Dis. 2025 Apr 25:ciaf210. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. KRISHNAN S, Scully EP
    Untangling the Sources of HIV-related Cardiovascular Risk.
    Clin Infect Dis. 2025 Apr 25:ciaf211. doi: 10.1093.
    PubMed    
    
    
    
77. YOON H, Pirofski LA, Boulware DR
    Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the need for Individualized Immune-Based Strategies.
    Clin Infect Dis. 2025 Apr 25:ciaf218. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. KIM S, Pelissari DM, Harada LO, Sanchez M, et al
    Long-term mortality trends among individuals with tuberculosis: a retrospective cohort study of individuals diagnosed with tuberculosis in Brazil.
    Clin Infect Dis. 2025 Apr 18:ciaf206. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. BREGER TL, Westreich DJ, Edmonds A, Edwards JK, et al
    Incidence of statin initiation among people with and without HIV in the US: a prospective observational study.
    Clin Infect Dis. 2025 Apr 17:ciaf207. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. MONTEPIEDRA G, Aaron L, Theron G, McCarthy K, et al
    Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics.
    Clin Infect Dis. 2025 Apr 16:ciaf198. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. KULIK GL, Mollner DC, Barbera L, Walker J, et al
    Application of Pragmatic Criteria to Assessments of Frailty and Physical Function among People with HIV.
    Clin Infect Dis. 2025 Apr 15:ciaf193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. SCOTT K, O'Rourke J, Jackson C, Ene L, et al
    Viral suppression, viral failure and safety outcomes in children and adolescents living with HIV on dolutegravir in Europe and Thailand.
    Clin Infect Dis. 2025 Apr 11:ciaf191. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. BAETEN JM
    Lenacapavir for Human Immunodeficiency Virus (HIV) Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences.
    Clin Infect Dis. 2025 Apr 9:ciaf116. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. HILL A, Siedner MJ, Fairhead C, Venter F, et al
    The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic.
    Clin Infect Dis. 2025 Apr 9:ciaf115. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. RIVERA-VILLEGAS H, Caro-Vega Y, Trujillo-Gamboa A, Lopez-Iniguez A, et al
    Differences in mortality in hospitalized advanced HIV disease between treatment-naive and treatment-discontinuing individuals: a comparative retrospective study from Mexico City.
    Clin Infect Dis. 2025 Apr 3:ciaf175. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. ZHU W, Delaney K, Huang YA, Patel RR, et al
    Real-world HIV RNA and antigen/antibody testing among people who use long-acting injectable PrEP.
    Clin Infect Dis. 2025 Apr 3:ciaf173. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. WENSING AM, Charpentier C, Calvez V, Ceccherini-Silberstein F, et al
    Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.
    Clin Infect Dis. 2025 Apr 3:ciaf161. doi: 10.1093.
    PubMed     Abstract available
    
    
    
88. DAVY-MENDEZ T, Napravnik S, Hogan BC, Eron JJ, et al
    Changes in the prevalence of non-AIDS conditions among hospitalized persons with HIV in the United States and Canada, 2008-2018.
    Clin Infect Dis. 2025 Apr 2:ciaf167. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. STEAD D, Wasserman S, Steenkamp E, Parrish A, et al
    Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus in East London, South Africa.
    Clin Infect Dis. 2025 Apr 2:ciaf080. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
90. GUARALDI G, Milic J
    A Metabolic Health Framework to Interpret Weight Gain Studies in People With Human Immunodeficiency Virus.
    Clin Infect Dis. 2025 Mar 28:ciae646. doi: 10.1093.
    PubMed    
    
    
    
91. GARCIA-RUIZ DE MORALES AG, Suarez Robles M, Perez-Elias MJ, Negredo E, et al
    Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in ART-naive Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
    Clin Infect Dis. 2025 Mar 28:ciae645. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. PEREZ-VALERO I, Mata DC, Espejo AC, Gallo M, et al
    Real-world effectiveness and safety of BIC/FTC/TAF in comparison with other regimens in people with HIV starting therapy with AIDS-defining conditions. Results from the CORIS Cohort: The ACTUAS II Study.
    Clin Infect Dis. 2025 Mar 27:ciaf162. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. BARTL L, Zeeb M, Kalin M, Loosli T, et al
    Machine Learning-Based Prediction of Active Tuberculosis in People with HIV using Clinical Data.
    Clin Infect Dis. 2025 Mar 25:ciaf149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. ADZEMOVIC T, Nalintya E, Fieberg A, Mande E, et al
    Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease.
    Clin Infect Dis. 2025 Mar 25:ciaf079. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. MEYEROWITZ EA, Schwartz IS
    Silence=Death Redux: Infectious Diseases, Public Health, and the Imperative to Resist.
    Clin Infect Dis. 2025 Mar 24:ciaf155. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. CUELLA-MARTIN I, Hakizayezu F, Ahmed A, Runyambo D, et al
    Paucibacillary tuberculosis drives the low positive predictive value of Xpert MTB/RIF Ultra for rifampicin resistance detection in low-prevalence settings.
    Clin Infect Dis. 2025 Mar 22:ciaf132. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. ROGG L, Underwood M, Hanan N, Castillo-Mancilla JR, et al
    Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.
    Clin Infect Dis. 2025 Mar 21:ciaf135. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. SODEKE O, Shah NS, Pals S, Riabokon S, et al
    Lower Tuberculosis Incidence Among People With Human Immunodeficiency Virus Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study.
    Clin Infect Dis. 2025 Mar 18:ciaf069. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. MATOGA MM, Chen JS, Sena AC, Ndalama B, et al
    High prevalence of Haemophilus ducreyi among patients with suspected primary syphilis in Malawi, 2019-2022.
    Clin Infect Dis. 2025 Mar 17:ciaf114. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. HASTIE E, Hill L, Bamford L, Karim A, et al
     Long-acting injectable HIV therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy.
     Clin Infect Dis. 2025 Mar 17:ciaf120. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. ROCKSTROH JK, Paredes R, Cahn P, Molina JM, et al
     Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial.
     Clin Infect Dis. 2025 Mar 13:ciaf077. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. CHARPENTIER C, Berzow D, Le Hingrat Q, Kaiser R, et al
     HIV-2EU - Supporting Standardized HIV-2 Drug Resistance Interpretation: an Update.
     Clin Infect Dis. 2025 Mar 12:ciaf110. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. VELAPHI S, Madewell ZJ, Tippett-Barr B, Blau DM, et al
     Investigating the role of cytomegalovirus as a cause of stillbirths and child deaths in low and middle-income countries through postmortem minimally invasive tissue sampling.
     Clin Infect Dis. 2025 Mar 10:ciaf098. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. CROWELL TA, Hsieh HC, Wang X, Chu X, et al
     Antiretroviral Therapy within Two Years of HIV Acquisition is Associated with Fewer Viral Blips: A Retrospective Analysis of Over 20 Years of Data from the U.S. Military HIV Natural History Study.
     Clin Infect Dis. 2025 Mar 10:ciaf103. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. DE MIGUEL R, de Lagarde Sebastian M, Blanco Arevalo JL, Pinto-Martinez A, et al
     Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons with Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicentre, Phase IIA Clinical Trial.
     Clin Infect Dis. 2025 Mar 7:ciaf100. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2025
106. SOGE OO, Thibault CS, Cannon CA, McLaughlin SE, et al
     Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization with Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus.
     Clin Infect Dis. 2025 Feb 28:ciaf089. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. BURGOS J, Curran A, Garcia J, Campany D, et al
     Effectiveness of electrocautery, topical cidofovir and topical sinecatechins for the Treatment of Anal High-grade Squamous Intraepithelial Lesions in Persons with HIV: an open-label, randomized controlled trial.
     Clin Infect Dis. 2025 Feb 27:ciaf086. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. VAN SICKELS N, Wong JWH, Villacorta-Cari E, Lee SE, et al
     State-of-the-Art Review: Data and Trust to Improve Care for Transgender and Gender-Diverse Patients.
     Clin Infect Dis. 2025;80:e16-e30.
     PubMed     Abstract available
     
     
     
109. OKUMURA N, Morino E, Nomoto H, Yanagi M, et al
     LC16m8 for Pre-exposure Prophylaxis against Mpox in a High-Risk Population: An Open-Label Randomized Trial.
     Clin Infect Dis. 2025 Feb 21:ciaf074. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. TZELIOS CA, Malatesta S, Carney T, White LF, et al
     Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis.
     Clin Infect Dis. 2025 Feb 20:ciae642. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. LUETKEMEYER AF, Chew KW, Lacey S, Hughes MD, et al
     Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.
     Clin Infect Dis. 2025 Feb 17:ciaf029. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. SAKURAI A, Ishikane M, Ohmagari N
     The Importance of Stratifying by Extremely Low CD4 Counts and Assessing Detailed Clinical Information for Clear Outcome Measures.
     Clin Infect Dis. 2025 Feb 7:ciaf058. doi: 10.1093.
     PubMed    
     
     
     
113. BENDER IGNACIO R, Kitahata M, Montano M, Shapiro A, et al
     Mpox in People with HIV: Prioritizing Interventions for those without HIV Viral Suppression.
     Clin Infect Dis. 2025 Feb 7:ciaf059. doi: 10.1093.
     PubMed    
     
     
     
114. TROYA J, Montes ML, Losa JE, Buzon-Martin L, et al
     Long-Acting CAB Plus RPV: It's Not About Weight, It's About the Weight of the Evidence.
     Clin Infect Dis. 2025 Feb 5:ciaf024. doi: 10.1093.
     PubMed    
     
     
     
115. COLLIER M, Chouchana L, Frange P, Sibiude J, et al
     Risk of Neurodevelopmental Disorders in Children Exposed to Human Immunodeficiency Virus and Antiretrovirals In Utero: A National Cohort Study in France.
     Clin Infect Dis. 2025 Feb 5:ciae610. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. GAISA M, Deshmukh A, Sigel K, Liu Y, et al
     2024 Anal Cancer Screening Guidelines: Analysis of Clinical Performance and HRA Utilization in a large Cohort of Persons with HIV.
     Clin Infect Dis. 2025 Feb 3:ciaf052. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. YU MA, Gerig L, Mehta CC, Musonge-Effoe J, et al
     Non-invasive markers of hepatic steatosis and fibrosis following INSTI initiation in women with HIV.
     Clin Infect Dis. 2025 Feb 3:ciaf049. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2025
118. GRENNAN T, Mohammed S, Edward J, Tattersall T, et al
     A pilot, randomized controlled trial of Dual Daily HIV and sexually transmitted infection pre-exposure prophylaxis using tenofovir disoproxil fumarate/emtricitabine and doxycycline in gay, bisexual and other men who have sex with men and transgender w
     Clin Infect Dis. 2025 Jan 30:ciaf043. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. BILIR SP, Krishnamurthy P, Karichu JK, Blosser SJ, et al
     Estimating the economic consequences of leveraging the novel cobas(R) HIV-1/HIV-2 Qualitative NAT Test in routine HIV testing.
     Clin Infect Dis. 2025 Jan 29:ciaf025. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. CHEMALY RF, Shafat T, Wald A, Kotton CN, et al
     Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials.
     Clin Infect Dis. 2025 Jan 29:ciae638. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. FORD SL, Felizarta F, Han K, Wang K, et al
     Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With Human Immunodeficiency Virus Type 1: A Substudy of the Phase 3b ATLAS-2M Study.
     Clin Infect Dis. 2025 Jan 29:ciae620. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. MARCUS JL, Weddle A, Kelley CF, Agwu A, et al
     Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.
     Clin Infect Dis. 2025 Jan 28:ciae648. doi: 10.1093.
     PubMed     Abstract available
     
     
     
123. WONDMENEH S, McDonald R, Quilter LAS, Workowski K, et al
     Reported Neurologic Manifestations Among Persons with Syphilis by Stage of Infection-12 States, 2019 -2022.
     Clin Infect Dis. 2025 Jan 17:ciaf015. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. KNUDSEN AD, Fuchs A, Benfield T, Kober L, et al
     HIV Is Associated With Subclinical Coronary Atherosclerosis: A Prospective Matched Cohort Study.
     Clin Infect Dis. 2025 Jan 16:ciae609. doi: 10.1093.
     PubMed     Abstract available
     
     
     
125. BARRE T, Ramier C, Wittkop L, Sogni P, et al
     Low CD4 cell count is associated with post-hepatitis C virus cure mortality in people living with HIV (ANRS CO13 HEPAVIH cohort).
     Clin Infect Dis. 2025 Jan 15:ciaf016. doi: 10.1093.
     PubMed    
     
     
     
126. MOYO M, Lawrence DS, Jafali J, Molloy SF, et al
     Recent Antiretroviral Therapy Initiation Is Associated With Increased Mortality Risk in Human Immunodeficiency Virus-associated Cryptococcal Meningitis: An Analysis of Clinical Trial Data From Africa.
     Clin Infect Dis. 2025 Jan 15:ciae586. doi: 10.1093.
     PubMed     Abstract available
     
     
     
127. MATELSKI A, Gregoire B, Beste LA, Varley CD, et al
     Analysis of Repeat Hepatitis C Viremia After Sustained Virologic Response in a Large Cohort of U.S. Veterans.
     Clin Infect Dis. 2025 Jan 9:ciaf008. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. 
     Correction to: Prediction of HIV Drug Resistance Based on Virologic, Immunologic, Clinical, and/or Adherence Criteria in the Stratall ANRS 12110/ESTHER Trial in Cameroon.
     Clin Infect Dis. 2025 Jan 7:ciaf001. doi: 10.1093.
     PubMed    
     
     
     
129. PESONEL E, Laouenan C, Guiraud L, Bourner J, et al
     Clinical characterisation and outcomes of human clade IIb mpox virus disease - a European multicentre observational cohort study (MOSAIC).
     Clin Infect Dis. 2025 Jan 3:ciae657. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. HUANG YS, Sun HY, Ho SY, Lin KY, et al
     Incidence and outcome of hepatitis D virus infection in people with HIV in the era of tenofovir-containing antiretroviral therapy.
     Clin Infect Dis. 2025 Jan 2:ciae655. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2024
131. MONTROUGE T, Bertine M, Peytavin G, Saint Joannis T, et al
     Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy with Lenacapavir-Containing Regimen.
     Clin Infect Dis. 2024 Dec 31:ciae650. doi: 10.1093.
     PubMed     Abstract available
     
     
     
132. RUFFIEUX Y, Mwansa-Kambafwile J, Metekoua C, Tombe-Nyahuma T, et al
     HIV-1 Viremia and Cancer Risk in 2.8 Million People: the South African HIV Cancer Match Study.
     Clin Infect Dis. 2024 Dec 30:ciae652. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. PEREZ NAVARRO A, Nutt CT, Siedner MJ, McCluskey SM, et al
     Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: A meta-analysis.
     Clin Infect Dis. 2024 Dec 26:ciae631. doi: 10.1093.
     PubMed     Abstract available
     
     
     
134. HAN WM, Solomon S, Smeaton L, Avihingsanon A, et al
     Reinfection and resistance associated substitutions following a minimal monitoring approach for HCV treatment in MINMON trial.
     Clin Infect Dis. 2024 Dec 20:ciae627. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. COUSSEMENT J, Heath CH, Roberts MB, Lane RJ, et al
     Management, outcomes and predictors of mortality of Cryptococcus infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand.
     Clin Infect Dis. 2024 Dec 18:ciae630. doi: 10.1093.
     PubMed     Abstract available
     
     
     
136. BJORNSON AM, Bedimo RJ, Szabo SM, Rochon H, et al
     Morbidity and Mortality Risk Among People With Human Immunodeficiency Virus and Central or Visceral Adiposity: A Targeted Literature Review.
     Clin Infect Dis. 2024 Dec 18:ciae543. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. EPLING BP, Lisco A, Manion M, Laidlaw E, et al
     Impact of Anti-CD4 Autoantibodies on Immune Reconstitution in People With Advanced Human Immunodeficiency Virus.
     Clin Infect Dis. 2024 Dec 18:ciae562. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. KHAN U, Rich M, Franke M, Lachenal N, et al
     The Frequency and Incidence of QT Prolongation with Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country MDR/RR-TB Cohort.
     Clin Infect Dis. 2024 Dec 10:ciae601. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. KAMKWALALA AR, Matthews A, Garg A, Roy U, et al
     The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With Human Immunodeficiency Virus (HIV).
     Clin Infect Dis. 2024 Dec 10:ciae518. doi: 10.1093.
     PubMed     Abstract available
     
     
     
140. BURMAN WJ, Hawkins KL
     Toward Evidence-based Recommendations for Laboratory Monitoring for Adolescents and Adults on Antiretroviral Therapy.
     Clin Infect Dis. 2024 Dec 10:ciae542. doi: 10.1093.
     PubMed     Abstract available
     
     
     
141. PINANA JL, Carbonell-Asins JA, Gomez D, Montoro J, et al
     Community-Acquired Respiratory Virus Infections: A Threat to Long-Term survivors after Allogeneic Stem Cell Transplant?
     Clin Infect Dis. 2024 Dec 5:ciae602. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. SWINDELLS S
     Bookends.
     Clin Infect Dis. 2024 Dec 5:ciae554. doi: 10.1093.
     PubMed    
     
     
     November 2024
143. MAGUIRE C, Rueve K, Farmer E, Huesgen E, et al
     Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir/rilpivirine.
     Clin Infect Dis. 2024 Nov 27:ciae579. doi: 10.1093.
     PubMed     Abstract available
     
     
     
144. FAUCI AS, Folkers GK
     HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.
     Clin Infect Dis. 2024 Nov 27:ciae585. doi: 10.1093.
     PubMed     Abstract available
     
     
     
145. MOUNZER K, Slim J, Ramgopal M, Hedgcock M, et al
     Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1).
     Clin Infect Dis. 2024 Nov 26:ciae522. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. CLEMENT ME, Hanscom B, Haines D, Bazan JA, et al
     Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083.
     Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. LANZ C, Meier J, Stockle M, Furrer H, et al
     HIV-1 low-level viremia predicts viral failure in participants on antiretroviral therapy in the Swiss HIV Cohort Study.
     Clin Infect Dis. 2024 Nov 21:ciae569. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. PUYAT JH, Brode SK, Shulha H, Romanowski K, et al
     Predicting risk of tuberculosis disease in people migrating to a low-TB incidence country: development and validation of a multivariable dynamic risk prediction model using health administrative data.
     Clin Infect Dis. 2024 Nov 20:ciae561. doi: 10.1093.
     PubMed     Abstract available
     
     
     
149. ROSEN LV, Thielking AM, Dugdale CM, Montepiedra G, et al
     Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks.
     Clin Infect Dis. 2024 Nov 15:ciae508. doi: 10.1093.
     PubMed     Abstract available
     
     
     
150. DAVIS JM, Rana A, Sax PE, Bares SH, et al
     Long-Acting Cabotegravir Plus Rilpivirine in People with HIV with Adherence Challenges and Viremia: Current Data and Future Directions.
     Clin Infect Dis. 2024 Nov 12:ciae557. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. PU J, Wu S, He JQ
     Efficacy and Safety of Systematic Corticosteroids treatment among HIV-Positive Patients with Tuberculosis: a systematic review and meta-analysis of randomized controlled trials.
     Clin Infect Dis. 2024 Nov 11:ciae563. doi: 10.1093.
     PubMed     Abstract available
     
     
     
152. JANI IV, Sabi I, Elsbernd K, Meggi B, et al
     Impact of point-of-care birth test-and-treat on clinical outcomes among infants with HIV: A cluster randomized trial in Mozambique and Tanzania.
     Clin Infect Dis. 2024 Nov 8:ciae530. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. LUO Q, Horner MJ, Haas CB, McGee-Avila JK, et al
     Differences in Trends in Cancer Incidence Rates Among People with HIV during 2001-2019 By Race and Ethnicity and By Risk Group in the United States.
     Clin Infect Dis. 2024 Nov 7:ciae555. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. DE WAAL R, Wools-Kaloustian K, Brazier E, Althoff KN, et al
     Global trends in CD4 count measurement and distribution at first antiretroviral treatment initiation.
     Clin Infect Dis. 2024 Nov 6:ciae548. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. ABELMAN RA, Ma Y, Mehta CC, Yang Q, et al
     Switch to Integrase Strand Transfer Inhibitors during the Menopausal Transition is Associated with Accelerated Body Composition Change in Women with HIV.
     Clin Infect Dis. 2024 Nov 4:ciae540. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. ACHHRA AC, Chan E, Applebaum S, Guerrero M, et al
     Five-year evaluation of Anal Cancer Screening Program in Men Who Have Sex With Men with HIV at Two Academic Center Clinics.
     Clin Infect Dis. 2024 Nov 4:ciae541. doi: 10.1093.
     PubMed     Abstract available
     
     
     
157. SPINELLI MA, Bisom-Rapp E, Heise MJ, Camp C, et al
     High Retention and Adherence with Rapid Long-Acting Injectable PrEP Implementation in an Urban Safety-Net Clinic Population.
     Clin Infect Dis. 2024 Nov 1:ciae531. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2024
158. DOMBROWSKI JC, Donnell D, Grabow C, Cohen SE, et al
     Evidence-Informed Provision of Doxycycline Post-Exposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections.
     Clin Infect Dis. 2024 Oct 30:ciae527. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. ORKIN C, Hayes R, Haviland J, Wong YL, et al
     Perspectives of people with HIV on implementing long acting cabotegravir plus rilpivirine in clinics and community settings in the UK: results from the anti-sexist, anti-racist, anti-ageist ILANA study.
     Clin Infect Dis. 2024 Oct 28:ciae523. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. HORBERG M, Thompson M, Agwu A, Colasanti J, et al
     Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America.
     Clin Infect Dis. 2024 Oct 12:ciae479. doi: 10.1093.
     PubMed     Abstract available
     
     
     
161. VIRDEE AK, Knudtzen FC, Llibre JM, Omland LH, et al
     Risk of tuberculosis after achieving HIV virological suppression on antiretroviral therapy: a Danish nationwide prospective cohort study.
     Clin Infect Dis. 2024 Oct 8:ciae499. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. MONTANO M, Shapiro AE, Whitney BM, Bamford L, et al
     Mpox in People With Human Immunodeficiency Virus: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort.
     Clin Infect Dis. 2024 Oct 8:ciae464. doi: 10.1093.
     PubMed     Abstract available
     
     
     
163. KIRK SE, Young C, Berry H, Hanson R, et al
     Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine.
     Clin Infect Dis. 2024 Oct 8:ciae472. doi: 10.1093.
     PubMed     Abstract available
     
     
     
164. HICKEY MD, Gistand N, Grochowski J, Mayorga-Munoz F, et al
     48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.
     Clin Infect Dis. 2024 Oct 5:ciae500. doi: 10.1093.
     PubMed     Abstract available
     
     
     
165. INZAULE S, Easterbrook P, Latona A, Ford NP, et al
     Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.
     Clin Infect Dis. 2024 Oct 3:ciae431. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2024
166. ROTH AM, Bartholomew TS, Ward KM, Groves A, et al
     Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs.
     Clin Infect Dis. 2024 Sep 30:ciae450. doi: 10.1093.
     PubMed     Abstract available
     
     
     
167. FAIRHEAD C, Levi J, Ramesh N, Hill A, et al
     Results from systematic review and meta-analysis of the efficacy and safety of two-drug versus three-drug ( Tenofovir/Lamivudine/Dolutegravir; TLD) regimens for HIV treatment.
     Clin Infect Dis. 2024 Sep 30:ciae490. doi: 10.1093.
     PubMed    
     
     
     
168. FONG Y, Dang L, Zhang B, Fintzi J, et al
     Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
     Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093.
     PubMed     Abstract available
     
     
     
169. LAHIRI CD, Mehta CC, Yang Q, Maramba T, et al
     "Short and Long-term Body Weight Change Following the Switch to or the Addition of Integrase Inhibitors in Persons with HIV Differs by Sex".
     Clin Infect Dis. 2024 Sep 26:ciae474. doi: 10.1093.
     PubMed     Abstract available
     
     
     
170. BEDIMO R, Hardy D, Lee D, Palella F, et al
     Expert Consensus Statement on an Updated Definition of Unintended Weight Loss Among Persons With Human Immunodeficiency Virus in the Modern Treatment Era.
     Clin Infect Dis. 2024;79.
     PubMed     Abstract available
     
     
     
171. GUTIERREZ F, Fernandez-Gonzalez M, Ledesma C, Losada-Echeberria M, et al
     Virological History Predicts Non-sustained Viral Suppression with Long-Acting Cabotegravir and Rilpivirine Therapy, independent of Pharmacokinetic Parameters.
     Clin Infect Dis. 2024 Sep 19:ciae475. doi: 10.1093.
     PubMed     Abstract available
     
     
     
172. MARTIN-CARMONA J, Corma-Gomez A, Tellez F, Arenga-Barrios D, et al
     No impact of HIV coinfection on the mortality in patients with hepatitis C virus infection after sustained virological response.
     Clin Infect Dis. 2024 Sep 18:ciae473. doi: 10.1093.
     PubMed     Abstract available
     
     
     
173. JOLY V, Ferre VM, Le Hingrat Q, Peytavin G, et al
     Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study.
     Clin Infect Dis. 2024 Sep 16:ciae447. doi: 10.1093.
     PubMed     Abstract available
     
     
     
174. VIDAL JE, Duarte AN, Chow FC, Duarte MIS, et al
     Does "Toxoplasma abscess" Properly Describe Brain Lesions Caused by Toxoplasma gondii?
     Clin Infect Dis. 2024 Sep 9:ciae463. doi: 10.1093.
     PubMed    
     
     
     
175. ANDERSON D, Ramgopal M, Hagins DP, Lee J, et al
     DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain.
     Clin Infect Dis. 2024 Sep 4:ciae449. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. EKE AC, Brummel SS, Aliyu MH, Stranix-Chibanda L, et al
     Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy.
     Clin Infect Dis. 2024 Sep 2:ciae441. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2024
177. GROENENDIJK AL, Miranda Afonso P, Wit F, Blaauw MJT, et al
     The risk of non-AIDS defining events is lower in ART-naive HIV controllers than in normal progressors on suppressive ART.
     Clin Infect Dis. 2024 Aug 29:ciae440. doi: 10.1093.
     PubMed     Abstract available
     
     
     
178. OGBUAGU O, Molina JM, Chetchotisakd P, Ramgopal MN, et al
     Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.
     Clin Infect Dis. 2024 Aug 29:ciae423. doi: 10.1093.
     PubMed     Abstract available
     
     
     
179. BOSMAN S, Ayakaka I, Muhairwe J, Kamele M, et al
     Evaluation of C-Reactive Protein and Computer-Aided Analysis of Chest X-rays as Tuberculosis Triage Tests at Health Facilities in Lesotho and South Africa.
     Clin Infect Dis. 2024 Aug 27:ciae378. doi: 10.1093.
     PubMed     Abstract available
     
     
     
180. GAKURU J, Kagimu E, Dai B, Okurut S, et al
     Implementation of single high-dose liposomal amphotericin B based induction therapy for treatment of HIV-associated cryptococcal meningitis in Uganda: a comparative prospective cohort study.
     Clin Infect Dis. 2024 Aug 24:ciae413. doi: 10.1093.
     PubMed     Abstract available
     
     
     
181. ERLANDSON KM, Umbleja T, Ribaudo HJ, Schrack JA, et al
     Pitavastatin is Well-Tolerated with no Detrimental Effects on Physical Function.
     Clin Infect Dis. 2024 Aug 19:ciae422. doi: 10.1093.
     PubMed     Abstract available
     
     
     
182. BERTHAUD V, Creech CB, Rostad CA, Carr Q, et al
     Safety and Immunogenicity of an mRNA-1273 Booster in Children.
     Clin Infect Dis. 2024 Aug 19:ciae420. doi: 10.1093.
     PubMed     Abstract available
     
     
     
183. GRISEL B, Kaur K, Swain S, Gorenshtein L, et al
     The Ethical Obligation to Treat Infectious Patients: A Systematic Review of Reasons.
     Clin Infect Dis. 2024;79:339-347.
     PubMed     Abstract available
     
     
     
184. RUPASINGHE D, Bansi-Matharu L, Law M, Zangerle R, et al
     Integrase strand transfer inhibitor (INSTI) related changes in BMI and risk of diabetes: a prospective study from the RESPOND cohort consortium.
     Clin Infect Dis. 2024 Aug 9:ciae406. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2024
185. FRIEDMAN JR, Abramovitz D, Skaathun B, Rangel G, et al
     Illicit Fentanyl Use and Hepatitis C Virus Seroconversion Among People Who Inject Drugs in Tijuana and San Diego: Results From a Binational Cohort Study.
     Clin Infect Dis. 2024 Jul 30:ciae372. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. BAI AD, Srivastava S, Martinez Cajas JL, Razak F, et al
     Community-acquired pneumonia in people with Human Immunodeficiency Virus (HIV) during the current era of effective antiretroviral therapy: A multi-center retrospective cohort study.
     Clin Infect Dis. 2024 Jul 27:ciae393. doi: 10.1093.
     PubMed     Abstract available
     
     
     
187. DITZENBERGER GL, Lake JE, Kitch DW, Kantor A, et al
     Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.
     Clin Infect Dis. 2024 Jul 24:ciae384. doi: 10.1093.
     PubMed     Abstract available
     
     
     
188. HIRUY H, Bala S, Byrne JM, Roche KG, et al
     FDA, CDC, and NIH Co-sponsored Public Workshop Summary-Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea.
     Clin Infect Dis. 2024 Jul 24:ciae386. doi: 10.1093.
     PubMed     Abstract available
     
     
     
189. MEYA DB, Nalintya E, Skipper CP, Kirumira P, et al
     Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With Human Immunodeficiency Virus (HIV)-Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen (CrAg) Titers.
     Clin Infect Dis. 2024 Jul 24:ciae266. doi: 10.1093.
     PubMed     Abstract available
     
     
     
190. KAUPPINEN KJ, Aho I, Sjoblom N, Tynninen O, et al
     Effect of Two Forms of Tenofovir on Duodenal Enterocytes - a Hypothesis for Different Effect of TDF and TAF on Body Weight and Plasma Lipids.
     Clin Infect Dis. 2024 Jul 23:ciae374. doi: 10.1093.
     PubMed     Abstract available
     
     
     
191. JARRETT BA, Shearer K, Motlhaoleng K, Chon S, et al
     Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With Human Immunodeficiency Virus in the North West Province of South Africa (the Teko Study): A Cl
     Clin Infect Dis. 2024 Jul 22:ciae268. doi: 10.1093.
     PubMed     Abstract available
     
     
     
192. SWARTZ TH, Aberg JA
     Collaborative Strategies for Antimicrobial Stewardship Programs: Navigating Financial and Regulatory Landscapes.
     Clin Infect Dis. 2024;79:272-273.
     PubMed    
     
     
     
193. FIERER DS, Carollo JR, Rodriguez-Caprio G, Radix A, et al
     Hepatitis C Virus Reinfection Among Men Who Have Sex With Men With HIV in New York City.
     Clin Infect Dis. 2024 Jul 18:ciae297. doi: 10.1093.
     PubMed     Abstract available
     
     
     
194. JILG N, Giganti MJ, Chew KW, Shaw-Saliba K, et al
     Severe Acute Respiratory Syndrome Coronavirus 2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With Coronavirus Disease 2019.
     Clin Infect Dis. 2024 Jul 17:ciae324. doi: 10.1093.
     PubMed     Abstract available
     
     
     
195. FAIRHEAD C, Levi J, Hill A
     Challenges for novel antiretroviral development in an era of widespread TLD availability.
     Clin Infect Dis. 2024 Jul 11:ciae361. doi: 10.1093.
     PubMed     Abstract available
     
     
     
196. GUTIERREZ F, Lopez L, Galera C, Tiraboschi JM, et al
     Early Detection of Cancer and Precancerous Lesions in Persons with HIV through a Comprehensive Cancer Screening Protocol.
     Clin Infect Dis. 2024 Jul 3:ciae359. doi: 10.1093.
     PubMed     Abstract available
     
     
     
197. MOHAREB AM, Barshak MB, Papaliodis GN, Sobrin L, et al
     Ocular syphilis in patients with nonreactive RPR and positive treponemal serologies: a retrospective observational cohort study.
     Clin Infect Dis. 2024 Jul 2:ciae354. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2024
198. KIMUDA S, Kwizera R, Dai B, Kigozi E, et al
     Comparison of early fungicidal activity and mortality between daily liposomal amphotericin B and daily amphotericin B deoxycholate among patients with HIV-associated cryptococcal meningitis.
     Clin Infect Dis. 2024 Jun 29:ciae326. doi: 10.1093.
     PubMed     Abstract available
     
     
     
199. COLLINS LF, Sheth AN, Tisdale T, Mehta CC, et al
     Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine among Reproductive-aged Women in the U.S. South.
     Clin Infect Dis. 2024 Jun 29:ciae331. doi: 10.1093.
     PubMed     Abstract available
     
     
     
200. FUSCO D, Malenica I, Gunthard HF, Gupta SK, et al
     Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison from Two Large, Open-Label Studies.
     Clin Infect Dis. 2024 Jun 26:ciae336. doi: 10.1093.
     PubMed     Abstract available
     
     
     
201. BORRE ED, Ahonkhai AA, Chi KK, Osman A, et al
     Projecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee.
     Clin Infect Dis. 2024 Jun 24:ciae243. doi: 10.1093.
     PubMed     Abstract available
     
     
     
202. BROWN L, Rautemaa-Richardson R, Mengoli C, Alanio A, et al
     Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis.
     Clin Infect Dis. 2024 Jun 11:ciae239. doi: 10.1093.
     PubMed     Abstract available
     
     
     
203. TAO G, Patel CG, He L, Workowski K, et al
     STI/HIV testing, STIs, and HIV PrEP use among men who have sex with men (MSM) and men who have sex with men and women (MSMW) in United States, 2019-2022.
     Clin Infect Dis. 2024 Jun 10:ciae314. doi: 10.1093.
     PubMed     Abstract available
     
     
     
204. SKRIVANKOVA VW, Huwa J, Muula G, Chiwaya GD, et al
     Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia.
     Clin Infect Dis. 2024 Jun 7:ciae261. doi: 10.1093.
     PubMed     Abstract available
     
     
     
205. ABBOTT R, Landsiedel K, Atukunda M, Puryear SB, et al
     Incident Tuberculosis Infection is Associated with Alcohol use in Adults in Rural Uganda.
     Clin Infect Dis. 2024 Jun 2:ciae304. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
206. ALEXANDRE M, Prague M, Lhomme E, Lelievre JD, et al
     Definition of Virological Endpoints Improving the Design of Human Immunodeficiency Virus (HIV) Cure Strategies Using Analytical Antiretroviral Treatment Interruption.
     Clin Infect Dis. 2024 May 31:ciae235. doi: 10.1093.
     PubMed     Abstract available
     
     
     
207. WEDDLE A
     Position of the Infectious Diseases Society of America and the HIV Medicine Association on Team-Based Infectious Diseases Care and the Roles of Advanced Practice Providers and Clinical Pharmacists.
     Clin Infect Dis. 2024 May 27:ciae265. doi: 10.1093.
     PubMed    
     
     
     
208. SAX PE
     Team-Based HIV Care is the Best Care.
     Clin Infect Dis. 2024 May 24:ciae264. doi: 10.1093.
     PubMed    
     
     
     
209. KONU YR, Takassi E, Peytavin G, Dapam N, et al
     Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo.
     Clin Infect Dis. 2024 May 15:ciae278. doi: 10.1093.
     PubMed     Abstract available
     
     
     
210. BURKE RM, Nyirenda SK, Mtenga T, Twabi HH, et al
     Enhanced tuberculosis diagnosis with computer-aided chest X-ray and urine LAM in adults with HIV admitted to hospital (CASTLE study): A cluster randomised trial.
     Clin Infect Dis. 2024 May 15:ciae273. doi: 10.1093.
     PubMed     Abstract available
     
     
     
211. UNIGWE I, Goodin A, Lo-Ciganic WH, Cook RL, et al
     Trajectories of Pre-exposure Prophylaxis Adherence Among Commercially Insured Individuals.
     Clin Infect Dis. 2024;78:1272-1275.
     PubMed     Abstract available
     
     
     
212. CARLUCCI JG, Huntington T, Technau KG, Yotebieng M, et al
     High Prevalence of Unconfirmed Positive HIV PCR Test Results among African Infants with HIV Exposure in the International epidemiology Databases to Evaluate AIDS (IeDEA) Consortium.
     Clin Infect Dis. 2024 May 14:ciae251. doi: 10.1093.
     PubMed     Abstract available
     
     
     
213. SHAH NS, Kityo C, Hughes MD, McCarthy C, et al
     Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries.
     Clin Infect Dis. 2024 May 13:ciae269. doi: 10.1093.
     PubMed     Abstract available
     
     
     
214. NYEIN PP, Petoumenos K, Borok M, Eriobu N, et al
     Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study.
     Clin Infect Dis. 2024 May 9:ciae256. doi: 10.1093.
     PubMed     Abstract available
     
     
     
215. SUN C, Yang Z, Wen Y
     Current knowledge about long-term liver outcome among HBV/HIV coinfected patients.
     Clin Infect Dis. 2024 May 7:ciae247. doi: 10.1093.
     PubMed    
     
     
     
216. VINIKOOR MJ, Lauer GM
     People with HBV/HIV coinfection should be prioritized in HBV cure research.
     Clin Infect Dis. 2024 May 7:ciae248. doi: 10.1093.
     PubMed    
     
     
     
217. SHORT WR, Zimmerman MM, Mohamed O, Mofenson LM, et al
     Safety Data Timelines for Pregnant Individuals with HIV on Antiretroviral Therapy.
     Clin Infect Dis. 2024 May 6:ciae249. doi: 10.1093.
     PubMed     Abstract available
     
     
     
218. ZHANG HL, Mock M, Bushman L, Anderson PL, et al
     Cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatitis B co-infection with differential viral suppression.
     Clin Infect Dis. 2024 May 3:ciae241. doi: 10.1093.
     PubMed     Abstract available
     
     
     
219. VAN DER WEKKEN-PAS L, Weiss F, Simon-Zuber C, Sebisch R, et al
     Cabotegravir and rilpivirine long acting injectables in a pregnant woman living with HIV.
     Clin Infect Dis. 2024 May 3:ciae242. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2024
220. HOLT LM, Short WR, Momplaisir F, Hyun E, et al
     Bictegravir Use During Pregnancy: A Multi-Center Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes.
     Clin Infect Dis. 2024 Apr 26:ciae218. doi: 10.1093.
     PubMed     Abstract available
     
     
     
221. TUSCH E, Ryom L, Pelchen-Matthews A, Mocroft A, et al
     Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
     Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093.
     PubMed     Abstract available
     
     
     
222. ROSENBERG NE, Shook-Sa BE, Young AM, Zou Y, et al
     An HIV-1 risk assessment tool for women aged 15-49 in African countries: A pooled analysis across 15 nationally representative surveys.
     Clin Infect Dis. 2024 Apr 24:ciae211. doi: 10.1093.
     PubMed     Abstract available
     
     
     
223. MWESIGWA B, Sawe F, Oyieko J, Mwakisisile J, et al
     Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
     Clin Infect Dis. 2024 Apr 24:ciae215. doi: 10.1093.
     PubMed     Abstract available
     
     
     
224. COYLE RP, Morrow M, Mann SC, Mainella V, et al
     Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).
     Clin Infect Dis. 2024 Apr 18:ciae212. doi: 10.1093.
     PubMed     Abstract available
     
     
     
225. WOHL DA, Koethe JR, Sax PE, McComsey GA, et al
     Antiretrovirals and Weight Change: Weighing the Evidence.
     Clin Infect Dis. 2024 Apr 12:ciae191. doi: 10.1093.
     PubMed     Abstract available
     
     
     
226. DAMAS J, Munting A, Fellay J, Haerry D, et al
     Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV.
     Clin Infect Dis. 2024 Apr 12:ciae189. doi: 10.1093.
     PubMed     Abstract available
     
     
     
227. HILL A
     Which form of tenofovir should be used worldwide: TDF or TAF?
     Clin Infect Dis. 2024 Apr 12:ciae190. doi: 10.1093.
     PubMed    
     
     
     
228. SHERMAN A, Tuan J, Cantos VD, Adeyiga O, et al
     COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.
     Clin Infect Dis. 2024 Apr 10:ciae192. doi: 10.1093.
     PubMed     Abstract available
     
     
     
229. BACHELARD A, Le Hingrat Q, Ferre VM, Le M, et al
     Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
     Clin Infect Dis. 2024;78:1005-1010.
     PubMed     Abstract available
     
     
     
230. CHABALA C, Wobudeya E, van der Zalm MM, Kapasa M, et al
     Clinical outcomes in children living with HIV treated for non-severe tuberculosis in the SHINE Trial.
     Clin Infect Dis. 2024 Apr 9:ciae193. doi: 10.1093.
     PubMed     Abstract available
     
     
     
231. CACHAY ER, Gilbert T, Qin H, Mathews WC, et al
     Clinical Predictors and Outcomes of Invasive Anal Cancer for People With Human Immunodeficiency Virus in an Inception Cohort.
     Clin Infect Dis. 2024 Apr 4:ciae124. doi: 10.1093.
     PubMed     Abstract available
     
     
     
232. RODRIGUEZ-MOLINO P, Tebruegge M, Noguera-Julian A, Neth O, et al
     Tuberculosis disease in immunocompromised children and adolescents: a pTBnet multi-centre case-control study.
     Clin Infect Dis. 2024 Apr 3:ciae158. doi: 10.1093.
     PubMed     Abstract available
     
     
     
233. PODANY AT, Cramer Y, Imperial M, Rosenkranz SL, et al
     Twice-Daily Dolutegravir Based Antiretroviral Therapy with One Month of Daily Rifapentine and Isoniazid (1HP) for TB Prevention.
     Clin Infect Dis. 2024 Apr 3:ciae183. doi: 10.1093.
     PubMed     Abstract available
     
     
     
234. TSCHUMI N, Lukau B, Tlali K, Motaboli L, et al
     Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho.
     Clin Infect Dis. 2024 Apr 3:ciae185. doi: 10.1093.
     PubMed     Abstract available
     
     
     
235. FAHERTY EAG, Holly T, Ogale YP, Spencer H, et al
     Investigation of an mpox outbreak affecting many vaccinated persons in Chicago, IL-March 2023-June 2023.
     Clin Infect Dis. 2024 Apr 3:ciae181. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
236. ROSTAD CA, Atmar RL, Walter EB, Frey S, et al
     A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US
     Clin Infect Dis. 2024 Mar 27:ciae173. doi: 10.1093.
     PubMed     Abstract available
     
     
     
237. BERTUMEN JB, Pascopella L, Han E, Glenn-Finer R, et al
     Epidemiology and Treatment Outcomes of Tuberculosis with Chronic Hepatitis B Infection-California, 2016-2020.
     Clin Infect Dis. 2024 Mar 26:ciae169. doi: 10.1093.
     PubMed     Abstract available
     
     
     
238. JAO J, Bonner LB, Dobinda K, Powis KM, et al
     Lower Insulin Sensitivity Through 36 Months of Life With in Utero HIV and Antiretroviral Exposure in Botswana: Results From the Tshilo Dikotla Study.
     Clin Infect Dis. 2024 Mar 26:ciae088. doi: 10.1093.
     PubMed     Abstract available
     
     
     
239. VALIN N, Lambert-Niclot S, Torres E, Meynard JL, et al
     A Human Immunodeficiency Virus Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.
     Clin Infect Dis. 2024 Mar 21:ciad757. doi: 10.1093.
     PubMed     Abstract available
     
     
     
240. BOODMAN C, Gupta N, Nelson CA, van Griensven J, et al
     Bartonella quintana Endocarditis: A Systematic Review of Individual Cases.
     Clin Infect Dis. 2024;78:554-561.
     PubMed     Abstract available
     
     
     
241. KRISHNAN S, Chaisson RE
     US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.
     Clin Infect Dis. 2024;78:514-517.
     PubMed     Abstract available
     
     
     
242. VANBAELEN T, Tsoumanis A, Kenyon C
     Total Antimicrobial Consumption in Doxycycline Postexposure Prophylaxis Cohorts and the Intensity of Screening for Bacterial Sexually Transmitted Infections.
     Clin Infect Dis. 2024;78:803-805.
     PubMed    
     
     
     
243. NGUYEN Q, Wooten D, Lee D, Moreno M, et al
     GLP-1 Receptor Agonists Promote Weight Loss Among People with HIV.
     Clin Infect Dis. 2024 Mar 19:ciae151. doi: 10.1093.
     PubMed     Abstract available
     
     
     
244. HAZRA A, Celum C, Luetkemeyer AF, Molina JM, et al
     Risk of antimicrobial resistance with doxy-PEP is real, as is the need for its well-Informed implementation.
     Clin Infect Dis. 2024 Mar 19:ciae152. doi: 10.1093.
     PubMed    
     
     
     
245. KENYON C
     We should not downplay the risks that doxycycline PEP will select for AMR.
     Clin Infect Dis. 2024 Mar 19:ciae139. doi: 10.1093.
     PubMed    
     
     
     
246. LANDOVITZ RJ, Tao L, Yang J, de Boer M, et al
     HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
     Clin Infect Dis. 2024 Mar 14:ciae143. doi: 10.1093.
     PubMed     Abstract available
     
     
     
247. MINTER DJ, Appa A, Chambers HF, Doernberg SB, et al
     The positioning of ceftobiprole in the treatment of Staphylococcus aureus bacteremia.
     Clin Infect Dis. 2024 Mar 11:ciae126. doi: 10.1093.
     PubMed    
     
     
     
248. NGO HX, Xu AY, Velasquez GE, Zhang N, et al
     Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
     Clin Infect Dis. 2024 Mar 11:ciae119. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2024
249. CROCKER-BUQUE T, Lachenal N, Narasimooloo C, Abdrasuliev T, et al
     Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.
     Clin Infect Dis. 2024 Feb 29:ciad767. doi: 10.1093.
     PubMed    
     
     
     
250. TEIXEIRA LAA, Santos B, Correia MG, Valiquette C, et al
     Long-term protective effect of tuberculosis preventive therapy in a medium/high TB incidence setting.
     Clin Infect Dis. 2024 Feb 26:ciae101. doi: 10.1093.
     PubMed     Abstract available
     
     
     
251. SALDANA CS, Burkhardt E, Pennisi A, Oliver K, et al
     Development of a Machine Learning Modelling Tool for Predicting HIV Incidence Using Public Health Data from a County in the Southern United States.
     Clin Infect Dis. 2024 Feb 23:ciae100. doi: 10.1093.
     PubMed     Abstract available
     
     
     
252. FOLLMANN D, Mateja A, Fay MP, Magaret CA, et al
     Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.
     Clin Infect Dis. 2024 Feb 19:ciae081. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2024
253. LITWIN AH, Akiyama MJ
     US Veterans Health Administration Hepatitis C Virus (HCV) Program - A Model for National HCV Elimination though Patient-Centered Medical Homes.
     Clin Infect Dis. 2024 Jan 27:ciae028. doi: 10.1093.
     PubMed    
     
     
     
254. YATES TA, Halliday N
     Re: Association of CMV DNAemia with Long-Term Mortality in a Randomized Trial of Preemptive Therapy (PET) and Antiviral Prophylaxis (AP) for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative (D+R-) Liver Transplant Reci
     Clin Infect Dis. 2024 Jan 9:ciae004. doi: 10.1093.
     PubMed    
     
     
     November 2023
255. HERBERT C, Manabe YC, Filippaios A, Lin H, et al
     Differential Viral Dynamics by Sex and Body Mass Index During Acute SARS-CoV-2 Infection: Results from a Longitudinal Cohort Study.
     Clin Infect Dis. 2023 Nov 16:ciad701. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2022
256. BHIMRAJ A, Morgan RL, Shumaker AH, Baden L, et al
     Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.
     Clin Infect Dis. 2022 Sep 5. pii: 6692369. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.